Close

Drug Research

Coriolis Pharma Expands ATMP Development Facilities

Coriolis Pharma, a provider of research and development of for (bio)pharmaceutical drugs, is expanding its advanced therapy medicinal products (ATMP) development facilities under biosafety level S2 (BSL2 / S2). Re-construction of an existing building near the Coriolis headquarters started in...

UNC researchers develop potential universal coronavirus vaccine

Scientists at the University of North Carolina Gillings School of Global Public Health have developed a universal vaccine that protected mice not just against COVID-19 but also other coronaviruses and triggered the immune system to fight off a dangerous...

mCureX and Samyang sign MoU for mRNA vaccine development

OliX Pharmaceuticals’ subsidiary mCureX has entered a memorandum of understanding (MoU) with Samyang Holdings to develop a messenger ribonucleic acid (mRNA) vaccine for Covid-19. The companies are co-developing a vaccine that could potentially target Covid-19 viral variants. According to the deal,...

AGC Biologics Heidelberg Facility to Further Supply Plasmid DNA for COVID-19 Vaccine

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced its partnership with BioNTech SE to further supply Plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine, at AGC’s Heidelberg, Germany facility. “We are honored...

Biogen and Eisai launch multiple initiatives to help patients with Alzheimer’s disease access ADUHELM

Following today’s U.S. FDA accelerated approval of ADUHELMTM  as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease by reducing amyloid beta plaques in the brain, Biogen  and Eisai Inc., U.S. subsidiary of...

Centivax partners with US NMRC to study Covid-19 antibody

Centivax has signed a strategic collaboration with the US Naval Medical Research Center (NMRC) to conduct Phase I clinical development of its SARS-CoV-2 antibody, Centi-B9. Centi-B9 is designed as a broad-spectrum therapeutic and prophylactic for administration through injections. It is...

Pacira BioSciences, Inc. partners with Ashfield Engage to deliver European commercial infrastructure

Ashfield Engage, part of UDG Healthcare plc, announced that it has been selected by US-based Pacira BioSciences, Inc. to provide strategic commercialization services for its non-opioid pain management products in select European countries. Pacira has partnered with Ashfield Engage to...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read